Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma

Choi,Ji  Eun; Noh,Sang  Jae; Lee,Ju  Hyung; Bae,Jun  Sang; Chu,Hyun  Hee; Park,Ho  Sung; Jang,Kyu  Yun; Chung,Myoung  Ja; Kang,Myoung  Jae; Lee,Dong  Geun; Moon,Woo  Sung

doi:10.3892/ol.2012.756

Expression of keratin 20 and its clinicopathological significance in intrahepatic cholangiocarcinoma

Authors:
- Ji Eun Choi
- Sang Jae Noh
- Ju Hyung Lee
- Jun Sang Bae
- Hyun Hee Chu
- Ho Sung Park
- Kyu Yun Jang
- Myoung Ja Chung
- Myoung Jae Kang
- Dong Geun Lee
- Woo Sung Moon
View Affiliations

Affiliations: Department of Pathology, Chonbuk National University, Medical School and Research Institute for Endocrine Sciences, Jeonju, Jeonbuk 561-756, Republic of Korea, Department of Preventive Medicine, Chonbuk National University, Medical School and Research Institute for Endocrine Sciences, Jeonju, Jeonbuk 561-756, Republic of Korea
Published online on: June 13, 2012 https://doi.org/10.3892/ol.2012.756
Pages: 534-540

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Although the expression of keratin 7 (K7) and K20 is considered to be a useful factor in the differential diagnosis of intrahepatic cholangiocarcinoma (ICC) and metastatic colorectal carcinoma (CRC) of the liver, a proportion of typical ICC retains K20 expression. The frequency and biological significance of K20 expression in ICC remains unclear. We analyzed the expression of K7, K19 and K20 in 66 surgically resected liver tumors consisting of 46 ICCs and 20 metastatic CRCs of the liver and 20 corresponding primary CRCs. In the 46 ICCs, K7, K19 and K20 were expressed in 40 (87%), 45 (98%) and 16 (35%) cases, respectively. K7, K19 and K20 were expressed in 1 (5%), 20 (100%) and 16 (80%) of the 20 primary CRCs and 2 (10%), 20 (100%) and 16 (80%) of the 20 metastatic CRCs, respectively. A combined K7/K20 profile was identified as a good predictor for differentiating ICC and metastatic CRC. K20 expression in ICC was significantly associated with male gender (P=0.034), hilar location (P=0.026), intraductal papillary type (P=0.006), intestinal phenotype (P<0.001) and MUC2 expression (P=0.008). Univariate analysis identified that poor patient survival was significantly associated with histological grade (P=0.020), invasion depth (P=0.005), lymph node metastasis (P=0.012), tumor stage (P=0.004) and vessel invasion (P=0.023). The tumor stage (P=0.002) was a poor independent prognostic indicator, while MUC6 expression (P=0.036) was a good independent prognostic indicator. The survival rate in patients with K20‑positive ICC was lower compared to that of patients with K20‑negative ICC, but was not statistically significant. Furthermore, the combined K7/K20 immunophenotype was identified to be useful for differentiating ICC and metastatic CRC. K20‑positive ICC displays specific characteristics with regards to tumor location and histological subtype. Additionally, MUC6 expression in ICC is a good independent prognostic factor, while K20 expression is more often associated with aggressive biological behavior.

View Figures

View References

1	Moll R, Franke WW, Schiller DL, Geiger B and Krepler R: The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell. 31:11–24. 1982. View Article : Google Scholar : PubMed/NCBI
2	Miettinen M: Keratin 20: immunohistochemical marker for gastrointestinal, urothelial, and Merkel cell carcinomas. Mod Pathol. 8:384–388. 1995.PubMed/NCBI
3	Maeda T, Kajiyama K, Adachi E, Takenaka K, Sugimachi K and Tsuneyoshi M: The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 9:901–909. 1996.PubMed/NCBI
4	Rullier A, Le Bail B, Fawaz R, Blanc JF, Saric J and Bioulac-Sage P: Cytokeratin 7 and 20 expression in cholangiocarcinomas varies along the biliary tract but still differs from that in colorectal carcinoma metastasis. Am J Surg Pathol. 24:870–876. 2000. View Article : Google Scholar : PubMed/NCBI
5	Shimonishi T, Miyazaki K and Nakanuma Y: Cytokeratin profile relates to histological subtypes and intrahepatic location of intrahepatic cholangiocarcinoma and primary sites of metastatic adenocarcinoma of liver. Histopathology. 37:55–63. 2000. View Article : Google Scholar
6	Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL and Trotti A: AJCC Cancer Staging Manual. 7th edition. Springer; New York, NY: 2010
7	Nakanuma Y, Curado MP, Franceschi S, Gores G, Paradis V, Sripa B, Tsui WMS and Wee A: Intrahepatic cholangiocarcinoma. WHO Classification Of Tumours Of The Digestive System. Bosman FT, Carneiro F, Hruban RH and Theise ND: 4th edition. IARC Press; Lyon: pp. 217–224. 2010
8	Moll R, Lowe A, Laufer J and Franke WW: Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am J Pathol. 140:427–447. 1992.PubMed/NCBI
9	Zen Y, Fujii T, Itatsu K, et al: Biliary papillary tumors share pathological features with intraductal papillary mucinous neoplasm of the pancreas. Hepatology. 44:1333–1343. 2006. View Article : Google Scholar : PubMed/NCBI
10	Nakanuma Y, Sasaki M, Ishikawa A, Tsui W, Chen TC and Huang SF: Biliary papillary neoplasm of the liver. Histol Histopathol. 17:851–861. 2002.PubMed/NCBI
11	Zen Y, Sasaki M, Fujii T, et al: Different expression patterns of mucin core proteins and cytokeratins during intrahepatic cholangiocarcinogenesis from biliary intraepithelial neoplasia and intraductal papillary neoplasm of the bile duct - an immunohistochemical study of 110 cases of hepatolithiasis. J Hepatol. 44:350–358. 2006.
12	Sugimachi K, Taguchi K, Aishima S, et al: Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma. Mod Pathol. 14:900–905. 2001. View Article : Google Scholar : PubMed/NCBI
13	Hidaka E, Yanagisawa A, Seki M, Setoguchi T and Kato Y: Genetic alterations and growth pattern in biliary duct carcinomas: loss of heterozygosity at chromosome 5q bears a close relation with polypoid growth. Gut. 48:656–659. 2001. View Article : Google Scholar : PubMed/NCBI
14	Isa T, Tomita S, Nakachi A, Miyazato, et al: Analysis of microsatellite instability, K-ras gene mutation and p53 protein overexpression in intrahepatic cholangiocarcinoma. Hepatogastroenterology. 49:604–608. 2002.PubMed/NCBI
15	Guedj N, Zhan Q, Perigny M, et al: Comparative protein expression profiles of hilar and peripheral hepatic cholangiocarcinomas. J Hepatol. 51:93–101. 2009. View Article : Google Scholar : PubMed/NCBI
16	Jain R, Fischer S, Serra S and Chetty R: The use of Cytokeratin 19 (CK19) immunohistochemistry in lesions of the pancreas, gastrointestinal tract, and liver. Appl Immunohistochem Mol Morphol. 18:9–15. 2010. View Article : Google Scholar : PubMed/NCBI
17	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
18	de Jong MC, Nathan H, Sotiropoulos GC, et al: Intrahepatic cholangiocarcinoma: an international multi-institutional analysis of prognostic factors and lymph node assessment. J Clin Oncol. 29:3140–3145. 2011.PubMed/NCBI
19	Briggs CD, Neal CP, Mann CD, Steward WP, Manson MM and Berry DP: Prognostic molecular markers in cholangiocarcinoma: a systematic review. Eur J Cancer. 45:33–47. 2009. View Article : Google Scholar : PubMed/NCBI
20	Linder S: Cytokeratin markers come of age. Tumour Biol. 28:189–195. 2007. View Article : Google Scholar : PubMed/NCBI
21	Aishima S, Asayama Y, Taguchi K, et al: The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma. Mod Pathol. 15:1181–1190. 2002. View Article : Google Scholar : PubMed/NCBI
22	Uenishi T, Yamazaki O, Tanaka H, et al: Serum cytokeratin 19 fragment (CYFRA21-1) as a prognostic factor in intrahepatic cholangiocarcinoma. Ann Surg Oncol. 15:583–589. 2008. View Article : Google Scholar : PubMed/NCBI
23	Higashi M, Yonezawa S, Ho JJ, et al: Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma. Hepatology. 30:1347–1355. 1999. View Article : Google Scholar : PubMed/NCBI
24	Park SY, Roh SJ, Kim YN, et al: Expression of MUC1, MUC2, MUC5AC and MUC6 in cholangiocarcinoma: prognostic impact. Oncol Rep. 22:649–657. 2009.PubMed/NCBI
25	Matsumura N, Yamamoto M, Aruga A, Takasaki K and Nakano M: Correlation between expression of MUC1 core protein and outcome after surgery in mass-forming intrahepatic cholangiocarcinoma. Cancer. 94:1770–1776. 2002. View Article : Google Scholar
26	Hong SM, Cho H, Moskaluk CA, Frierson HF Jr, Yu E and Ro JY: CDX2 and MUC2 protein expression in extrahepatic bile duct carcinoma. Am J Clin Pathol. 124:361–370. 2005. View Article : Google Scholar : PubMed/NCBI
27	Tamada S, Goto M, Nomoto M, et al: Expression of MUC1 and MUC2 mucins in extrahepatic bile duct carcinomas: its relationship with tumor progression and prognosis. Pathol Int. 52:713–723. 2002. View Article : Google Scholar : PubMed/NCBI
28	Boonla C, Wongkham S, Sheehan JK, et al: Prognostic value of serum MUC5AC mucin in patients with cholangiocarcinoma. Cancer. 98:1438–1443. 2003. View Article : Google Scholar : PubMed/NCBI
29	Aishima S, Kuroda Y, Nishihara Y, et al: Gastric mucin phenotype defines tumour progression and prognosis of intrahepatic cholangiocarcinoma: gastric foveolar type is associated with aggressive tumour behaviour. Histopathology. 49:35–44. 2006. View Article : Google Scholar
30	Thuwajit P, Chawengrattanachot W, Thuwajit C, Sripa B, Paupairoj A and Chau-In S: Enhanced expression of mucin 6 glycoprotein in cholangiocarcinoma tissue from patients in Thailand as a prognostic marker for survival. J Gastroenterol Hepatol. 23:771–778. 2008. View Article : Google Scholar : PubMed/NCBI